Ziprasidone hydrochloride drug description, Exporters, Importers, drug description, Molecular Formula C21H21ClN4OS.HCl;C21H22Cl2N4OS, Molecular Weight 449.40, CAS Registry Number 138982-67-9, drugs Suppliers, Uses, Generic Products, Distributors, Side Effects, bulk drugs, Anti-Bacterial, Warnings, Ziprasidone Distributors, api, active pharmaceuticals ingredients, Information Drugs, Importers, drug Technology, FDA, hydrochloride, Taj Pharmaceuticals LTd.

Sitemap | Contact Us

Welcome To Taj Pharmaceuticals Ltd API

Ziprasidone-Hcl Taj API

India

Latin America/ Caribbean

Africa & Middle East

Asia

Russia

Europe

Ziprasidone Hcl Manufacturers in India Suppliers Ziprasidone Hcl Exporters Distributors Ziprasidone Hcl api active pharmaceuticals ingredients Ziprasidone Hcl manufacturers Side Effects bulk drugs raw material Ziprasidone Hcl companies Side Effects Importers Ziprasidone Hcl Ziprasidone Hcl Exporters Ziprasidone Hcl exporters FDA Ziprasidone Hcl DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Ziprasidone Hydrochloride manufacturing pharmaceutical drugs pharmaceutical intermediates Ziprasidone Hydrochloride pharmaceutical chemicals pharmaceutical raw materials Ziprasidone Hydrochloride active pharmaceutical ingredients Ziprasidone Hydrochloride committee active pharmaceutical ingredients manufacturer Ziprasidone Hydrochloride Active Pharmaceutical Ingredients manufacturer Ziprasidone Hydrochloride exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Ziprasidone Hcl, Ziprasidone Hcl manufacturer India, Ziprasidone Hcl product, Ziprasidone Hcl products, Api preparation, Certificate of Analysis API manufacturer product, Ziprasidone Hcl anti ulcer product, Certificate of Origin COA Ziprasidone Hcl COS Ziprasidone Hcl, pharmaceutical generic, pharmaceutical drug, medical, Ziprasidone Hcl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Ziprasidone Hcl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Ziprasidone Hcl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Ziprasidone Hcl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Ziprasidone Hcl ingredients, api, HIV Ziprasidone Hcl, tablets, capsules, syrup & protein Ziprasidone Hcl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Ziprasidone Hcl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Ziprasidone Hcl WHO, UKMHRA Approval

	PRODUCT LIST
	Home
	API >>>
	Pharmaceuticals API List
	Chemicals
	Manufacturing
	Product Development
	Product Search
	Agro Chemicals
	Custom Pharma Services
	Contact Us

taj pharma ltd. Ziprasidone-Hcl

HOME >> API >> API List 3 >> Ziprasidone Hcl >> Drug Description

DRUG DESCRIPTION
Ziprasidone Hcl CAS Registry Number 138982-67-9

Ziprasidone Hcl Capsules contain a monohydrochloride, monohydrate salt of ziprasidone. Chemically, ziprasidone hydrochloride monohydrate is 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, monohydrochloride, monohydrate. The empirical formula is C21H21ClN4OS · HCl · H2O and its molecular weight is 467.42. Ziprasidone hydrochloride monohydrate is a white to slightly pink powder.

Ziprasidone Hcl is available as Capsules for oral administration and is most effective when taken with food. It has been approved for treatment of schizophrenia.

Ziprasidone Hcl is a serotonin dopamine antagonist that works to treat the positive, negative, and depressive symptoms associated with schizophrenia. Positive symptoms include visual and auditory hallucinations and delusions. Negative symptoms, which are harder to treat, include blunted affect, social withdrawal, and lack of motivation.

Schizophrenia is a chronic illness that requires lifelong treatment.

The efficacy of Capsules ( hydrochloride) as a treatment for schizophrenia was established in four short-term, four to six week trials and one long-term 52 week trial. All were placebo-controlled studies in inpatients, most of whom met DSM III-R criteria for schizophrenia. Each trial evaluated two or three fixed doses of , ranging from 20 to 100 mg,

Information Associated with Product:

DRUG DESCRIPTION >>

DOSAGE

SIDE EFFECTS

PRECAUTIONS

INTERACTION

CONSUMER INFORMATION

PDF DOWNLOAD

WORD DOCUMENT


Product Enquiry	Product Quotation	Sample Request	Place Your Order

Taj Pharmaceuticals API Logo

Investor Relations Feedback Contact Worldwide Sitemap

© 2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.